BSE filing, BSE: 544738. Summary written from the filing by ALFA Finder's alert engine.
Speciality Medicines Ltd: key numbers
- Share price
- ₹136.00
- Market cap
- ₹119.5 Cr
- Revenue (annual)
- ₹75.29 Cr
- Net profit (annual)
- ₹13.03 Cr
- P/E (TTM)
- 9.2×Sector 46.1×
- Promoter holding
- 43.43%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Speciality Medicines Ltd
All →Speciality Medicines Other Announcement
Speciality Medicines Ltd has submitted its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI Regulation 31.
Speciality Medicines Annual General Meeting
Speciality Medicines Limited conducted its 5th Annual General Meeting on September 28, 2026. Shareholders considered the adoption of FY26 audited financial statements and the re-appointment of Director Sumit Goyani.
Speciality Medicines Annual Report
Speciality Medicines Limited has submitted its Annual Report for the financial year 2025-26 to the exchange, complying with regulatory filing requirements.
Speciality Medicines Annual General Meeting
Speciality Medicines Limited scheduled its 5th Annual General Meeting for September 28, 2026. The board also approved the draft Directors' Report for FY 2025-26.
Speciality Medicines Regulatory Approval
Speciality Medicines Limited received regulatory approval in Ethiopia for two additional pharmaceutical formulations, Olanzapine and Diazepam tablets. The company now has 12 registered products in Ethiopia.
Speciality Medicines Business Update
Speciality Medicines Limited received regulatory approval for two new products, Olanzapine and Diazepam tablets, in the Ethiopian market, strengthening its international export portfolio.
Other other announcement announcements
All →Refractory Shapes Other Announcement
Refractory Shapes Ltd filed its Integrated Governance filing for the quarter and half year ended 30 Sep 2026. It claims exemption from the Corporate Governance Report and reported zero investor grievances.
Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.